Form 4 for ABOS Acumen Pharmaceuticals, Inc.
Accepted 2026-06-17 17:10:15 ET · period of report 2026-06-15 · accession 0001628280-26-043987 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-06-17 17:10 | 2026-06-15+ | ABOS | Porter Derrell | Dir | M - OptEx | $1.07 | +19.5K | 48.5K | +67% | +$20.9K |
| DM | 2026-06-17 17:10 | 2026-06-15+ | ABOS | Porter Derrell | Dir | S - Sale+OE | $2.33 | -32.3K | 35.5K | -48% | -$75.2K |
| DM | 2026-06-17 17:10 | 2026-06-15+ | ABOS | Porter Derrell | Dir | M - OptEx | $0.00 | -19.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-15 | M | A | 6,460 | $1.07 | 54,760 | D | — | — | |
| 2 | Common | Common Stock | 2026-06-15 | S | D | 6,460 | $2.35 | 48,300 | D | — | — | |
| 3 | Common | Common Stock | 2026-06-16 | S | D | 12,800 | $2.33 | 35,500 | D | — | — | (F1) The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.305 to $2.345. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2026-06-17 | M | A | 13,040 | $1.07 | 48,540 | D | — | — | |
| 5 | Common | Common Stock | 2026-06-17 | S | D | 13,040 | $2.33 | 35,500 | D | — | — | |
| 6 | Derivative | Stock Option (right to buy) | 2026-06-15 | M | D | 6,460 | $0.00 | 13,040 | D | $1.07 · — to 2035-06-04 | 6,460 Common Stock | (F2) The shares subject to the option vested in full on the date of the 2026 annual stockholder meeting. |
| 7 | Derivative | Stock Option (right to buy) | 2026-06-17 | M | D | 13,040 | $0.00 | 0 | D | $1.07 · — to 2035-06-04 | 13,040 Common Stock | (F2) The shares subject to the option vested in full on the date of the 2026 annual stockholder meeting. |